Department of Oral and Craniomaxillofacial Surgery, Center for Dental Medicine, University Medical Center Freiburg, Freiburg, Germany; Berta-Ottenstein-Programme for Clinician Scientists, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
J Stomatol Oral Maxillofac Surg. 2020 Nov;121(5):599-603. doi: 10.1016/j.jormas.2019.12.012. Epub 2020 Jan 2.
Salivary duct carcinoma (SDC) is a rare and highly aggressive neoplasm of the salivary glands associated with high rates of local and distant recurrence and poor overall survival. We present a patient with SDC, who relapsed despite extensive multimodal therapy including surgery, postoperative radiochemotherapy, and heavy ion therapy. In the recurrent setting, immunohistochemical analysis confirmed androgen receptor positivity, prompting initiation of combined androgen deprivation therapy (ADT), which resulted in a fast and durable remission of the local tumor now lasting for 26 months. Analyzing the histopathologic specimens of all SDC patients treated at our department since 2009, we found significant AR expression in all patients. This is in line with other reports found in current literature and indicates AR positivity as a consistent feature of SDC, supporting ADT as a viable therapeutic option for SDC.
涎腺导管癌（SDC）是一种罕见且高度侵袭性的涎腺肿瘤，具有较高的局部和远处复发率及较差的总体生存率。我们报告了一例 SDC 患者，尽管接受了包括手术、术后放化疗和重离子治疗在内的广泛多模态治疗，但仍复发。在复发的情况下，免疫组化分析证实雄激素受体阳性，促使开始联合雄激素剥夺治疗（ADT），导致局部肿瘤迅速且持久缓解，目前已持续 26 个月。分析自 2009 年以来在我科治疗的所有 SDC 患者的组织病理学标本，我们发现所有患者均有明显的 AR 表达。这与目前文献中的其他报道一致，表明 AR 阳性是 SDC 的一个一致特征，支持 ADT 作为 SDC 的一种可行治疗选择。
